BRADLEY SAENGER - 27 Feb 2024 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role
Chief Financial Officer
Signature
/s/ Bradley Saenger
Issuer symbol
TNXP
Transactions as of
27 Feb 2024
Net transactions value
$0
Form type
4
Filing time
29 Feb 2024, 17:07:19 UTC
Previous filing
24 Feb 2023
Next filing
27 Feb 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNXP Stock Option Award $0 +282,000 $0.000000 282,000 27 Feb 2024 Common Stock 282,000 $0.3680 Direct F1, F2
transaction TNXP Stock Option Award $0 +282,000 $0.000000 282,000 27 Feb 2024 Common Stock 282,000 $0.4600 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
F2 The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.